We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Lung-specific expression of active Raf kinase results in increased mortality of influenza A virus-infected mice.
- Authors
Ölschläger, Veronika; Pleschka, Stephan; Fischer, Timo; Rziha, Hanns-Joachim; Wurzer, Walter; Stitz, Lothar; Rapp, Ulf R; Ludwig, Stephan; Planz, Oliver
- Abstract
Alterations in signalling via the Raf/MEK/ERK pathway interfere with influenza A virus replication in cell culture. While virus yields are reduced in cells expressing dominant-negative Raf or ERK, virus propagation is enhanced upon expression of constitutively active Raf or MEK. To study the impact of active Raf on influenza virus propagation in vivo, we investigated transgenic mice expressing an activated mutant of c-Raf (Raf-BxB) in the main target tissue of influenza virus, the lung. Raf-BxB expression results in multicentric alveolar adenomas. Influenza virus A infection of Raf-BxB mice results in increased disease symptoms and higher mortality rates. The immune response against viral pathogens in transgenic animals did not differ from wild-type mice as determined by the use of a Pseudorabies virus (PRV) as a model for a viral infection not affecting the lung. No significant differences of influenza virus titers in the lung of Raf-BxB and wild-type mice were observed. However, immunohistology revealed increased numbers of influenza NP-positive cells in the alveolar linings of Raf-BxB mice, demonstrating the strong tropism of influenza virus for cells expressing active Raf. These findings disclose the possibility to use modified influenza virus for the therapy of tumors with an activated Ras/Raf signalling pathway.Oncogene (2004) 23, 6639-6646. doi:10.1038/sj.onc.1207883 Published online 5 July 2004
- Subjects
ORTHOMYXOVIRUSES; RESPIRATORY infections; INFLUENZA; LABORATORY mice; COMMUNICABLE diseases; MORTALITY
- Publication
Oncogene, 2004, Vol 23, Issue 39, p6639
- ISSN
0950-9232
- Publication type
Article
- DOI
10.1038/sj.onc.1207883